SPOTLIGHT: Lilly wants to buy out 500 workers


Add up to 500 Eli Lilly workers to the pharma layoff toll. The Indianapolis-based pharma plans to offer buyout packages to 2,000 manufacturing and engineering employees who work on active ingredients for Humalog and Humulin insulin products and the Forteo osteoporosis med. The deals are designed to cut up to 500 jobs, primarily in manufacturing, but a few in R&D as well. Report

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."